Skip to main content
. 2016 Feb;7(1):112–121. doi: 10.3978/j.issn.2078-6891.2015.132

Table 1. Best reported survival with CRS/HIPEC compared to systemic therapy.

Cancer IP therapy Median survival (months)
References
IP therapy Systemic therapy
Appendiceal CRS/HIPEC ± EPIC 196 117.6* (1,29)
Colorectal CRS/HIPEC ± EPIC 62.7 23.9 (30)
Mesothelioma CRS/HIPEC ± EPIC 92 12.1 (31,32)

*, iterative CRS alone. CRS, cytoreductive surgery; HIPEC, hyperthemic intraperitoneal chemoperfusion; EPIC, early postoperative chemoperfusion.